Good morning. My name is Rob, and I will be your conference operator today. At this time, I would like to welcome everyone to the Organigram Holdings Inc. second quarter fiscal 2022 results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, again, press the star 1. Thank you. Craig MacPhail, you may begin your conference.
on today's call should be aware that it will contain estimates and other forward-looking information from which the company's actual results could differ. Please review the cautionary language in today's press release on various factors, assumptions, and risks that could cause our actual results to differ. Further, reference will be made to certain IFRS measures during the call, including adjusted EBITDA and adjusted gross margin. These measures do not have any standardized meaning under IFRS, and our approach in calculating these measures may differ from that of other issuers, so these measures may not be directly comparable. Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. Please see today's earnings report for more information about these measures.
Listeners should also be aware that in making certain statements relating to market share data, the company relies on reputable third-party data providers. I would now like to introduce Beena Goldenberg, Chief Executive Officer of Organigram Holdings Inc. Please go ahead, Ms. Goldenberg.
Thank you, and good morning, everyone. With me is Derek West, our Chief Financial Officer. For today's call, we'll discuss the financial results for the three months ended February 28, 2022, and I will provide a general business update. We will then open the call for questions. I'm happy to report that second quarter of fiscal 2022, we continued the progress of the past several quarters. We again achieved record net revenue in the quarter, the highest in the history of the company. We grew our market share and now hold the number three position among Canadian LPs in the recreational market in Canada. Most importantly, we achieved a positive adjusted EBITDA of CAD 1.6 million, 2 quarters earlier than we projected at the start of the year.
In the quarter, as we announced in our last call, we acquired Laurentian, an artisanal craft grower and premium hash producer based out of Quebec. The net revenue in Q2 was CAD 31.8 million, a 117% increase over Q2 of fiscal 2021. This is a record level of net revenue for Organigram and demonstrates our continuing success at understanding consumer needs, innovating to best address market demand, and introducing compelling brands and products that resonate. We continue to grow our market share. In February, we secured the number three position in market share among Canadian LPs for the second month in a row with a share of 8.2%, according to Hifyre. In March, the momentum continued with another twenty basis points gain for a market share of 8.4%.
We also continue to hold the number one position in the flower category, which represents about half of the Canadian cannabis market. Our SHRED milled flower products are the top sellers in Canada, with SHRED Tropic Thunder being the best-selling flower product in the country. We also hold the number three position in the gummies category, having doubled our market share quarter-over-quarter, with two of our SKUs among the top 10 best sellers in the country. This market position includes SHRED'ems Gummies, which were introduced this past August, and Monjour, our large format CBD-infused soft chews, introduced this past November. Edison Jolts, our unique high-potency THC lozenge, maintains its best position as a bestseller in the ingestible extracts category. Now moving on to innovation. We recognize the need to bring newness to the category, so we continue to launch new products.
We have leveraged our SHRED brand that has achieved high visibility among cannabis consumers. In March, we shipped SHRED X Kief-Infused Blends, an innovative product that combines the convenience and popularity of SHRED milled flower with the potency of kief in a 50/50 ratio. We also launched SHRED X vapes. These are 510 cartridge vapes with the flavor profiles of SHRED milled flower products, Tropic Thunder, Megamelon, and Funk Master. How are we doing? Well, within days of launch, SHRED X Tropic Thunder was the fourth best-selling vape in Ontario. Building on the success of SHRED'ems Gummies, we added unique line extensions. SHRED'ems POP! in the classic pop flavors of cola, root beer, and cream soda were introduced in March. We've also added two new sour flavors, Sour Apple Slap and Sour Blue Razzberry.
With eight SKUs now available to consumers, we expect to strengthen our market position in the gummy category. We've also added two new premium strains to our Edison line with Edison Kush Cakes and Edison Frozen Lemons. These high potency and terpene-rich additions will create further engagement with cannabis enthusiasts. With Big Bag o' Buds, our large format value brand, we added Pink Cookies, a high potency indica strain. This expansion of our product line addresses the desire for specific strains by value-seeking consumers and reflects the evolution of the Canadian cannabis market. International sales also bolstered our Q2 results. We shipped approximately 1,700 kilograms of dry flower to Israel and Australia in the quarter, marking the highest international B2B shipments in the history of the company.
We expect to have further shipments to Canndoc in Israel and Cannatrek in Australia in fiscal 2022, and we'll look to expand our international partners to ship more wholesale dry flower. Now let's look at operations, beginning with Laurentian. After acquiring Laurentian in December, we began working on integration. One of our priorities was to increase the distribution of its unique Tremblant Hash and Laurentian craft flower products. At acquisition, Laurentian products were available in four provinces. By the end of the fiscal year, we will be available in all ten. In Ontario, we've been successful at increasing distribution levels of Tremblant Hash from 25% to almost 40% of Ontario's 1,500 stores and have grown sales by 21%. This Ontario example underscores our success in leveraging our marketing, distribution, and field sales capabilities to drive results.
We expect to be able to achieve the same success across Canada as we increase the footprint of Laurentian brands. We are also making progress in expanding and automating production at Laurentian. Construction and licensing for the additional space is expected to be complete by the summer of 2022, with a 4x increase in cultivation capacity and increased automation, processing, and storage space to be achieved by the end of 2022. Hash production at Laurentian is now supported by high-quality and high-potency kief coming from our Moncton facility. This was identified as an acquisition synergy. At our Moncton campus, we are completing the Phase 4C expansion and expect to reach upwards of 80,000 kilograms of dried flower capacity. Environmental enhancements are currently in place in approximately 40% of the facility and should be fully implemented by the end of the year.
These upgrades have and will continue to further enhance yield and flower quality as they are completed. We currently have 2 automated pre-roll lines and will be adding high-speed pouch filling lines for SHRED and Big Bag o' Buds by the end of fiscal 2022. In Winnipeg, adding on to our highly automated gummy production line, we have automated labeling and excise stamping and are commissioning pouch packaging equipment. We have also upgraded and leveraged our warehouse to optimize our logistics network and drive freight savings. These changes help improve our efficiencies, margins, and customer service. The build-out and improvements in Moncton and Winnipeg reflect our strategy to make investments based on recognized business needs and strong payback. In the quarter, all large-scale construction projects were substantially completed at the Product Development Center of Excellence in Moncton.
The biolab is being fully equipped in Q3, and then we will begin to conduct advanced plant science research. In the quarter, our joint R&D efforts continue to progress well, and we look forward to applying the discoveries and deep scientific knowledge to both strengthen our existing market products as well as develop new consumer-centric innovations. It's important to note that BAT's support for the product development collaboration and Organigram as a whole was further showcased at the beginning of March when they invested CAD 6.3 million into the company. This investment was made through the exercise of their top-up rights pursuant to an investor rights agreement and increased their equity position from 18.8% to 19.4%.
Also, as mentioned in our call last quarter, in December, we increased our cumulative investment in Hyasynth Biologicals by CAD 2.5 million to CAD 10 million for a strong minority position. Hyasynth Biologicals' advanced research into using biosynthesis to produce THC, CBD, and rare cannabinoids without using cannabis plants provides us with another avenue to innovate in the future. Through these collaborations and in addition to our in-house R&D capabilities, we will continue to produce unique, exciting products for the Canadian consumers and, subject to terms of the PDC, create proprietary IP that we can introduce globally. Now I will turn it over to Derek to present the financial overview. Derek?
Thanks, Beena. Turning to our earnings results for Q2 fiscal 2022, gross revenue grew 128% from Q2 2021 to CAD 43.9 million, and net revenue grew 117% from the same period in fiscal 2021 to CAD 31.8 million. These revenue increases were primarily due to higher recreational net revenue, which grew 108% from Q2 of fiscal 2021, and the completion of international shipments to Israel under our agreement with Canndoc and to Australia through Cannatrek. While gross sales grew 128%, cost of sales decreased 20% year-over-year to CAD 25 million. Lowering our total cost of sales during a growth period was as a direct result of increased efficiencies at our production facilities, combined with improved inventory management.
We harvested approximately 10,000 kilos of flower during Q2 of fiscal 2022, compared to about 4,500 kilos in Q2 of fiscal 2021, an increase of 125%. Over the past year, the company has experienced a growing demand for its products, and this led to increased planting and cultivation levels, which when combined with higher flower yields per plant than as compared to the prior year's comparison quarter, this resulted in the doubling of our harvest. Largely due to a higher net revenue, a reduction in inventory provisions, unabsorbed inventory costs, and a lower cost of sales per unit, the gross margin in Q2 improved to CAD 6.9 million from CAD -16.5 million in Q2 of 2021.
On an adjusted basis, gross margin was CAD 8.3 million compared to a negative CAD 700 thousand in Q2 of fiscal 2021. We expect that we can continue to achieve efficiencies and better economies of scale from the three facilities lowering production costs. This, combined with contributions from higher-margin products, will further improve margins. SG&A, excluding non-cash share-based compensation, increased to CAD 14 million in Q2 2022 from CAD 10.3 million during the prior year's comparison quarter. This was largely due to higher employee costs due to increased headcount, including the acquisition of Laurentian, general wage increases, increased professional fees due to technology investments, and higher trade investments in marketing spend initiatives. In the quarter, we achieved positive adjusted EBITDA of CAD 1.6 million, a CAD 9.4 million improvement over a negative CAD 7.8 million in last year's comparison quarter.
This is the result of the continual improvements in our business, including higher sales volume, lower production costs, which generated higher gross margins and operating income. We achieved positive adjusted EBITDA two quarters earlier than projected at the start of the year. Based on the momentum we see in terms of increased sales and improved efficiencies, we expect to generate positive adjusted EBITDA into the future. Net loss for the quarter was CAD 4 million compared to a net loss of CAD 66 million in Q2 of fiscal 2021. This large reduction in the net loss was due to the increased sales and higher gross margins I've already mentioned.
In terms of our statements of cash flows, cash used in operating activities was less than CAD 1 million during Q2 of fiscal 2022, compared to cash used of CAD 10 million in Q2 of fiscal 2021. The year-over-year improvement is primarily due to the current period's operating income. Cash provided by financing activities was CAD 6 million during Q2 fiscal 2022, compared to CAD 51 million cash used in the prior year's quarter. During the current quarter, the company received CAD 6.3 million from proceeds from shares issued to BAT. Cash used in investing activities was CAD 23 million during Q2 fiscal 2022, compared to cash provided of CAD 18 million in Q2 of fiscal 2021.
The cash used in Q2 of this year reflects CAD 7 million in cash consideration for the acquisition of Laurentian, CAD 2.5 million for the additional investment in Hyasynth, CAD 8.7 million for facility expansion and improvements, and CAD 4.5 million invested into restricted cash to be used to fund the Center of Excellence. In terms of our balance sheet, on February 28, 2022, we had 151 million in unrestricted cash and short-term investments, compared to 184 million at the end of fiscal 2021. The decrease during fiscal 2022 is primarily due to the company's investment in its working capital assets and capital expenditures for facility improvements, the purchase of Laurentian, and the additional investment in Hyasynth. This concludes my comments. Thank you.
I would like to turn the call back to Beena.
Thanks, Derek. The first half of fiscal 2022 has shown the success of our strategy to create exciting products and brands that are embraced by the market to maintain efficient operations and deploy capital wisely. This will continue to be our focus, which positions us for success for the rest of the year. I'll reiterate that our investors can continue to expect strong revenue and volume growth driven by expanded distribution, more new and exciting product and brand introductions, continued international sales, further improvements in our adjusted gross margin, and continued positive adjusted EBITDA. Thank you for joining us today. I look forward to updating you on our progress. Now, operator, you may open the call for questions.
At this time, I would like to remind everyone in order to ask a question, press star, then 1 on your telephone keypad. Our first question comes from the line of Aaron Grey from Alliance Global Partners. Your line is open.
Hi. Good morning, and congratulations on the quarter and reaching the EBITDA target two quarters ahead of what you originally expected. First question for me, just on the EBITDA. Thinking about the EBITDA margin opportunity longer term, right? Now you've reflected into EBITDA profitability, expect that to continue going forward. Just how best do you think about, you know, the EBITDA margin opportunity maybe in the next 18-24 months as you expect, you know, continued improvement on the gross margin side and sales ramping up? Thank you.
Derrick, over to you on that one.
Okay. Yeah, we're confident that we'll continue positive adjusted EBITDA based on momentum over the past few quarters. Into the future with the increase to our capacity at all our facilities, this will result in economies of scale, which will lower our production cost, which will improve margins. There's also as well the additional contribution from Laurentian, which has a higher average price per unit just based on it being a premium product. This as well contributes to a positive margin. Bear in mind that as we need to continue to invest in our business to support the continued growth. While we expect to have a growing EBITDA, you know, we're not providing specific guidance at this time in terms of the percent of revenue.
We do expect, with all the momentum we have with increasing sales demand, increased capacity to have higher sales throughput with lower cost per unit, that ultimately we are well-positioned to have increases to our EBITDA over time.
Great. Thank you so much for that color and detail. Second question for me on international. I saw a nice sequential increase once again in the quarter. Looks like you're expecting for continued, you know, momentum there on that front. I just wanted to clarify specifically in terms of the shipments during the quarter, was there anything on the timing side? Do you feel like those are gonna be, you know, recurring? Is this a good, you know, run rate going forward? Then just any color you could provide maybe on the margin. I know it's a higher margin, and we've kind of gone over this before, but the margin differential in terms of, you know, the international versus the domestic revenue. Thank you.
Right. Thank you for the question. First of all, we do expect to see ongoing shipments to both Israel and Australia. You know, we obviously turn the paperwork, import quotas, import documents, export documents and need to get those turned before every shipment. That continues to be the regular cadence of our business, and we expect to see more shipments obviously for the balance of this year. In terms of your question on margin, I mean, the real answer is, you know, there's no excise tax on international B2B sales, and that's the significant improvement in margin over just general recreational sales. It obviously comes with different kind of testing requirements, there's a bit of offset to that.
It's good margin business and nicely complements our recreational business.
All right. Thank you very much, and congratulations on the quarter. I'll turn it back to the queue.
Thank you.
Your next question comes from the line of Tamy Chen from BMO Capital Markets. Your line is open.
Great. Thank you. Good morning. First question I had is specifically on your rec sales. You described how you're continuing to see momentum and your market share has continued to expand. I'm just curious, like why did your net rec revenues decline a little bit quarter-over-quarter?
We have a bit of a timing. Overall, Tamy, our momentum is solid, and we saw our market share grow again in March. We had a bit of a challenge during the month of January with Omicron as it ran through our facility and we had some high absenteeism that impacted our fulfillment. We had the highest shipping month in February to get product out. But we had some sort of a little bit of timing issue that rolled into some solid momentum into the month of March. That's what you're seeing on the rec side of the business. Our market share continues to grow, so the offtake isn't a problem.
We did have a little bit of timing issue through the quarter as a result of that, disruption.
Okay. I understand. My follow-up question is, so if I look at the broader Hifyre and even the StatsCan retail sales data for the industry, it seems to be slowing down or stalling a little bit the last several months, really since the fall. I noticed that you also produced a bit less flower, though I suppose that's attributed to the Omicron aspect. I guess two-part question here with respect to what's been happening in the market. First is, you called out for your fiscal Q3 that you're expecting market growth in your outlook. So are you seeing now that the industry is growing again to new highs?
Second part of the question is, based on where the market is today and what you expect over the near term, do you still believe that once you're at the, I think, almost 80,000-kilogram capacity, the market can still more than absorb that from you? Thank you.
Perfect. A couple of key questions there, Tammy. First of all, we do see the market picking up. It has been a little bit stalled over the last few months, as Stats Can has reported. Given the opening of the you know, communities and we expect to see concerts this summer and fairs, and we expect to see the opening up generally of social activity. We do expect to see the market to rebound over the course of the next few months, especially expecting a nice big lift coming up at 4/20. Yes, we think that it will rebound over the summer and we'll start to see the benefit of you know, those interactions.
I think we missed, you know, some of the challenges we had even in the last few quarters where it stalled. You know, Quebec had this issue where they had required the vaccine passport to just get into the cannabis retail stores. There was a little bit of a disruption from COVID over the last few months that had stalled the category. We expect with all the openings coming that we will see a rebound for sure. That's with regard to the market growth. Sorry, could you repeat your second part of the question?
Yeah, sure. I was just wondering where you see it going, the near term, perhaps even medium term of the market. Like, are you still confident that once you reach your full capacity at Moncton, the market can still, you know, more than absorb that, do you think?
Right. Okay, sorry. Yeah. On that front, you know, number one, we do see some continued growth. As I mentioned on our last call, our current situation is that demand is outstripping our supply. We have, you know, our SHRED product is currently only being shipped to Ontario, Alberta, and we have some shipments going into Quebec, not meeting those needs, so we have limited our distribution to other provinces, which is something that we will certainly expand once we have more capacity. Then for now, we are a net buyer of product. We have to buy flower to meet the current demand.
We don't have any concerns about using the capacity we have in our Moncton expansion, as we are already buying product from external suppliers that we will buy from in-house once we have it up and running.
Great. Thank you.
Your next question comes from the line of Matt Bottomley from Canaccord Genuity. Your line is open.
Good morning. Congrats on the print this morning, and thanks for taking these questions. You know, maybe just at a higher level when it comes to what's happening in the Canadian market, just sort of piggybacking off of what Tammy was talking about as well. Just the fact that if you look at some of the incumbents in the space that started with, you know, close to 20% market share on recreational implementation in Canada, it's consistently been coming down where I think the leader in the space now has, you know, maybe a little over 10% market share. Where do you see this bottoming out, even though that Organigram has been doing very well and re-accelerating as of late?
If you look at commoditized markets in the U.S. like Colorado, Oregon, you know, market leaders there barely sort of eke out 5%. I'm just curious where you think this is going in Canada, barring any sort of major change in excise tax or federal re-regulations in terms of the ability to secure, you know, outsized market share.
Thank you, Matt. First of all, I think that you know, when you look at some of the bigger players who had 20% market share that dropped down to 10%, I think one of the things that we see when we look at their performance is that you can't sit on your laurels. You can't sit with a product that's out in the marketplace and think it's gonna keep delivering the sales delivered last quarter or the quarter before. You have to keep innovating. A lot of the focus of my comments this morning was around innovation. We know this is a category that needs to constantly be refreshed, bring new news, bring new innovation, excite the consumers. I think that's something that we focused a lot of our time on.
We introduced, you know, 90 new products over the course of the last 12 months. We focus a lot on rationalizing, taking out slower movers, bringing in new products just to keep it fresh, and this is something that I think has helped our momentum continue over the course of time. I think the question about what's gonna happen long term, it's a highly fragmented market. We all know that there's a lot of small players that have less than 1% of market share, and that amount of players has grown. However, we also know that the provincial boards are starting to tighten up. They don't wanna carry, you know, thousands of duplicate products. They wanna manage how many items they have in their lineup.
One example I could share is as we took our Tremblant Hash out to some of the new provinces to get it listed, the feedback we got was they were excited that it was part of our portfolio because we're already a supplier to them, and they don't have to set up another vendor. They were. You know, they might not have taken the Tremblant Hash from a unique vendor, but they were happy to have it in our portfolio. I think that's a message that we have to recognize as this market matures, that provinces are gonna wanna deal with less vendors, and the vendors that are full suppliers of a cross-portfolio are going to be, you know, the prioritized. We're gonna have first access. We're gonna have better opportunity to get better distribution, get our listings in, and that's gonna help.
I think that as it matures, you're gonna find some of those smaller players sort of drop off. You are gonna see a consolidation, but in the bigger players, you know, the need to keep it fresh, keep bringing in new news is very important, and that's been our focus.
Great. Much appreciated. Just one follow-up for me on the consolidation part. You know, we've seen, you know, over the last several years, you know, 6 or more acquisitions for these types of craft growers. Many of them have actually turned out quite favorably in terms of their penetration or market share being a little more sustainable when it comes to pricing. Is there any other product categories or SKUs or classifications you think are kinda next in line for the industry to consolidate, or just sort of any other commentary on where you think M&A is going in the domestic elements of Canada?
First of all, I think we've seen different types of M&A over the last few years. There's been the big players who've acquired other big players, and as a result, had a lot of duplication in offerings and drove some obviously synergies, but some rationalization of brands as well. Whereas one of the things that we focus on our M&A strategy has been looking at our portfolio and seeing where there's gaps in our portfolio and really looking to find acquisitions that could fill those gaps. The example when we acquired EIC, Edibles and Infusions Corporation last April, we weren't in the gummy space, right? We acquired it in April. It was pre-revenue. By August, we launched the new gummies into the marketplace.
We're now the number three gummy player, right? In six months from when we launched into the market. We found that hole. We recognized with our Laurentian acquisition that we needed a craft flower provider. We weren't in concentrates, and concentrates was a growing segment, and we wanted to bolster our presence in the Quebec marketplace. That's working really well for us. Not only did we get the benefit of the higher margin products that Laurentian has provided, but we've strengthened our relationship with the SQDC in Quebec, and we're seeing that reflected in the growth of our core Organigram SKUs, not just the Tremblant SKUs.
We've been very focused at looking at the portfolio and figuring out where we have to go that meets it, so it is accretive and incremental as opposed to just chasing market share that ends up with duplication, might result in some rationalization. That's sort of our approach. In terms of your thoughts, where it's gonna go, look, there's a lot of players in flower and there's. You know, flower is a big part of the category, but how do you differentiate over time is gonna be important.
I think the you know, some of the fragmentation in the flower space is, you know, people want news, but the bigger players could keep bringing new strains, new news, and you don't need to have a separate you know, LP come out and set up for a one-time offer in and out. We you know, we're really focused on our quality of our flower, growing it, improving both our terpenes and our THC and developing high quality product for our Edison brand and bringing some new strains out in the marketplace so they, the retailers don't feel they need to chase those craft or specialty producers. Of course, we have our Laurentian craft flower as well.
That's how we see it and hopefully could keep growing and driving our market share as a result of that M&A approach.
Yeah. Great. Appreciate all the color.
Thank you.
Your next question comes from the line of Douglas Miehm from RBC Capital Markets. Your line is open.
Thanks very much. My first question really has to do with your strategic thinking, being as it relates to, pricing in the marketplace. It seems you've done an excellent job from that perspective. Do you think some of the pricing declines in the marketplace that we've seen over the last 12 months are over? Are we at a base, or could we see some further erosion in overall pricing in the Canadian marketplace?
Right, Doug. I think I talked about this last quarter. I think a lot of the price compression that we saw in flower has happened. I think we got to a point where flower pricing on the value segment is actually, you know, at or even slightly below what the illicit market is at. I think that pressure on flower is mostly behind us. We've also seen with less supply in the market in Canada, we've had some, you know, grow cultivation sites that have been shuttered. We've got a bit more balance between supply and demand that was pushing some of that price compression as well. The flower piece I think is mostly behind us. There is more compression that we'll expect to see.
We see it in vapes, we see it in concentrates. I think the important thing is that for us, recognizing that, we don't shy away from the value segment. We think it's an important segment. It's a high volume segment. If you could make margin in the value segment and then build some more premium offerings in terms of your mix, you know, you've got it made. You can continue to drive your positive EBITDA. You know, I think that there could be other compression in some of those other segments until they reach that point where they're lining up to what the illicit market was offering. That's, you know, that's the pressure point.
Once, you know, people could buy the product through retail stores, you know, legal retail stores and get at the same price, and really, if you look at some of the research results, you know, more, better quality product, you know, like why would you know, that's where it will settle down. Hopefully that provides the color you were looking for.
Yeah, no, very helpful. As a follow-up, you know, what we're finding, and I don't think this is a surprise, but budtenders play a key role in, you know, focusing on what type of product people should buy. What do you think, and an apparent preference for the smaller guy as well relative to larger LPs. So they do support the craft growers probably to a more significant extent than the larger players. What's your thinking on that? I know that you'll probably describe your strains and your innovation, but is there anything else that you can add as well?
Listen, I think you're right. Budtenders do play a very important role because consumers, there are consumers that come into those retail stores, and they're asking questions and want some guidance on what to buy. I think one of the things that we pride ourselves at Organigram is we have our own dedicated sales force. We have feet on the street across the country. We spend a lot of time engaging with budtenders, not only sharing with them, you know, what our products, our strains are, but we do education programs with them. We run, you know, we go in and we set up in-store activations. We have relationships in store, and we promote, you know, the breadth of our portfolio.
If there is a budtender that's focused on craft or more premium flowers, we'll focus a lot of our attention on our Edison brand or bring in our Laurentian craft flower now. You've got some budtenders that are really looking for the innovative products. When we introduce something like our SHRED X kief-infused blends, you know, we're introducing something new and exciting that's high potency. You know, really great feedback on our Tremblant hash as we've taken the education of what hash is out to the marketplace, how it's used, and done a lot of education with the budtenders.
You know, in our gummies, look, we came into the market with products that were at a price point that was more accessible to a lot of consumers, and we got a lot of positive feedback from the budtenders that, you know, now people could buy, you know, a 4 gummies for under CAD 5 as opposed to the, you know, CAD 8 that was being charged before, and a significant benefit. I think there's, you know, it's not all about price, it's about price and value and, you know, uniqueness and offering, and all those factor into what a budtender might recommend to a consumer. We spend a lot of time with that connection with budtenders, talking about our portfolio, and we feel that they often recommend our products.
It's not just the little guy that they recommend. They're recommending quality products, and we feel we have a really good portfolio.
Excellent. Thank you very much.
Thank you.
Your next question comes from the line of Ty Collin from Eight Capital. Your line is open.
Hi. Thanks for taking my question, and congrats on the really solid improvement in gross margin this quarter. Could you help us unpack the key moving pieces there in terms of what drove that gross margin improvement? Just, you know, how much of that was due to Laurentian, how much from the larger international shipments, how much from product mix, for example? Appreciate any color you could provide there. Thanks.
Okay. Perfect. Thanks, Ty. Derek, I'll pass that over to you.
Perfect. I would say you outlined a couple of the points that were key in terms of improving the margin, but it was a little bit of everything in terms of product mix. No question there was more with the international shipment, which has been outlined earlier with the excise tax. It has a much higher margin than most rec flower does. That was helpful. Though generally, we have an increase as well as the contribution from Laurentian, which, as a craft grow and with the hash product does attract higher margins in that business, and there was a contribution there that did assist the quarter.
I think the other element that's really key is just with overall continued sales growth over the last few quarters and with higher levels of production. We're just starting to achieve economies of scale and getting a lower cost of production on an overall basis, which is helping the margin in all our product categories. And we expect that lift to continue as we look forward, given that we harvested 10,000 kilos in the quarter. That's an annualized rate of 40,000. We do believe we'll leave the fiscal year at 80,000 and that we have the capacity to sell that product on, as per our flow-through. Where just a large component of our costs are fixed in nature, just by operating at these higher levels, we do over time get a lower cost per unit.
This is just providing a general lift for the company in the quarter and then as was partially seen last quarter as well. We expect this to continue.
Great. Thanks for that. Just for my follow-up, a bit more of a market-level question. Given some of the pressures on consumers' pocketbooks here between inflation and rising borrowing costs, are you seeing customers starting to trade down into value categories at all, and is that a risk to your plan to kind of emphasize more premium SKUs in your sales mix?
Yeah. First of all, I think our sales mix. Look, we have a lot of value products, and I think that we don't shy away from them. We could make margin on our value products as well as our premium. You have to be able to meet different consumers are driven by different sensitivities. Obviously, there's a big consumer group that are looking for the lower-priced products. Still high quality, but lower price. There are the cannabis enthusiasts and sort of craft seekers that want the higher quality products. We wanna make sure we're offering the different products to the different consumers what they're looking for. In terms of pressures to the pocketbook, there's no question. We all know that cost of living has gone up.
I think what we saw over the course of COVID was that people were buying into the cannabis market to address stress, to address relaxation. It wasn't all about partying and discretionary. It became more of a you know something to help them get through some of the challenges. Look, while I'd like to admit that we're excited about more of the recreational time over the summer, the pressure on you know inflation and cost increases is out there. We think that our products offer consumers an opportunity to you know address those stresses and feel you know and feel good about you know their day, right?
It's a little bit of a help and a little bit, you know, and it's an important addition to, I think, their lifestyle. I don't really expect there would be a very big impact other than perhaps more of a shift to the more value products. That will, of course, benefit us. We're happy to be a value supplier along with a premium supplier.
Great. Thanks, Beena. Thanks, Derek.
Your next question comes from a line of Frederico Gomes from ATB Capital Markets. Your line is open.
Hi, good morning. Thanks for taking my questions. Just on your gross margin, you guys are showing some good growth there, a good expansion. Can you talk about the differences in margins between your rec sales in Canada and your international sales, and how much of that margin expansion is coming from a mix with higher international? Thank you.
Derek?
I'll take that. Yes. Well, I guess our international revenues were CAD 4.4 million in Q2, which is, you know, one of the highest that we've had as a total and as a percent to our total revenue. As a company, as noted, we don't have the excise on it. It does attract a much higher margin than our rec business, despite our margins also improving in our rec business as well. We've been lowering the cost of production at the facility, and this is helpful for all product categories, including pre-rolls as well. We don't publicly disclose, I guess, our margin by distribution channel, and so it's a difficult question to answer in the sense that we just don't provide that specific guidance.
The international shipments are an important part of our business. We have a cadence of ensuring that we try to have quarterly shipments, and we will expect to continue to do so. The both businesses are growing, and we expect to have more flower available at the end of the year to supply both these markets. When we do so, it'll be at a lower cost per unit just from economies of scale. In terms of getting granular on what is the margin by distribution channel, that's just guidance we haven't historically provided or published. Apologies. It's not the clearest answer to the question, but it's just not guidance we provide.
Yeah. No, no, sure. I understand that. Thank you. And then when you look at your market share and your growth outlook through the remainder of this year, which product categories do you expect you will gain most market share in? You know, we know that you are a leader in flower, but you know, do you expect to gain a lot of share in edibles, vapes or continue to gain share in flower? Any color on specific product categories. Thank you.
Right. Thanks, Fred. Listen, we just launched a bunch of new products. We're very excited about our SHRED X vapes. It's a known fact that we are very underdeveloped in this segment, and we have a great brand in SHRED, with, you know, bold flavors, and we could reproduce those flavors in our vape offerings. Initial uptake, we have shipped to New Brunswick, sold out very quickly on our initial shipment. We do expect to see some growth coming from our vape launch. You know, as I mentioned in my point earlier, we have a bunch of new innovation coming into the gummies space. You know, really on our SHRED'ems, building out that lineup from three SKUs to eight provides us bigger presence.
We expect to continue to drive our market share on the gummies segment. You know, we are seeing great results in certain retailers where we're you know already the number one gummies supplier. That certainly is you know a goal of ours to continue to drive the growth in the gummies space. With regard to concentrates, remember, we only had basically two months of Laurentian in our Q2 results. We do expect to see not only an increase based on you know having the full quarter, but obviously, as I mentioned, we're expanding our distribution. We've started to ship to some of the Atlantic provinces already. We have shipments expected to go out to BC.
That expanded distribution on concentrates on top of, you know, the extra volume just from a full quarter should help us really increase our market share on the concentrates section as well. I would say that while flower is obviously very important, we're number one in flower, and we'll keep driving, you know, to fill flower requirements. Where we see our biggest market share gains are gonna be from some of those 2.0 categories that we believe could strengthen, you know, our full breadth of portfolio, but will also improve our margins. They tend to be higher margin segments as well.
Thank you. That's really helpful. Congrats on the quarter again. Back to you.
Your next question comes from the line of Owen Bennett from Jefferies. Your line is open.
Good morning, guys. Hope all well. First question, I just wanted to come back to the sales mix. Obviously, really impressive market share traction, but does appear to be driven at the value end with SHRED and a lot of the new launches are also with SHRED. I was just wondering, could you give maybe a bit more color on your actual sales mix currently between value and premium? And then what you're doing exactly to address the top end of the market. Obviously, you've got Laurentian, you've got Edison, but interested in how you see that sales mix evolving going forward or how you'd like to see it evolve in an ideal world. Thank you.
Right. Thank you. Let me say that our flower sales, if I look at the mix over time, you know, if I go back to fourth quarter of 2021, we had about 68% of our business was our flower, and 18% were our blends, which was our SHRED. If you fast-forward to this quarter, you know, the flower went from 68% to 58%, and blends held roughly the same from 18% to 19%. These are % of our total revenue. I guess the message is, you know, we're holding our position in flower by continuing to innovate and bring new strains and meet the consumer needs. The focus on our growth has really been in expanding some of those other areas, right?
I mean, edibles, obviously new to us in our fourth quarter at 3%, now represents 9% of our business in Q2. Concentrates, which we didn't have, now represents 5%. You know, I forgot to mention earlier, we have the number one SKU in the ingestible extracts category with our Jolts, the high-potency lozenge that we have out in the marketplace. It really is, it's unique, it's differentiated, patent pending, and it continues to grow. There's a lot of interest in that product, and we've just introduced a couple new flavors into the marketplace. The mix is changing by adding 2.0 products while continuing to make sure we have, you know, news and unique offerings in our flower and in our blends.
Okay, thanks. The next question is, I mean, how are you trending currently with the available capacity? When will construction on Moncton be completed? Just linked to that, how much of a boost do you think to gross margins would you foresee when Moncton is complete and running at full scale? Thank you.
Right. I'll start, and then I'll pass it over to Derek to answer the question on the gross margins. Currently, we're running at capacity. We are, you know, basically, as I mentioned earlier, our demand is outstripping our supply. As soon as product comes off the line, gets through our testing and our packaging, we're shipping it out the door. You know, what's ending up in the marketplace is fresh, high-quality flower. We are, I mean, you know, we don't have any spare capacity, so we are currently buying from external customers, making sure obviously the quality meets our specification, and look forward to when we'll be able to, you know, supply our own product as the expansion comes online.
Your question of when do we expect that, we expect to be planting in the 4C expansion by the end of Q3, and we expect to be harvesting flower out of those new rooms in Q4 of this year. We're well on our way, very excited about getting the extra capacity. As I said, beyond you know, there's opportunity to expand our distribution of SHRED into some other markets, which we haven't been able to do. And we have you know, we'll explore further opportunities as we you know, we have the capacity to provide it. We've been somewhat restricted, and we look forward to having that extra capacity. Derek, over to you on the margins.
Yeah. I think when comparing Q2 of this year to Q2 of last year, it sort of demonstrates the impact to the financials just on changing production levels. In Q2 of 2021, we were harvesting, you know, approximately 4,000 kilos in a quarter, and we ended up reporting in that quarter a negative adjusted gross margin, so a negative 5%.
Just by moving up to our current capacity, which was in and around the 40-45,000 level prior to completing construction, along with other process improvements and initiatives at the facility, we've taken that negative adjusted gross margin, and in this print for Q2, we have a 26% adjusted gross margin, a 31% swing. Now I'm not indicating that I'm expecting a similar growth to margin, in terms of an extra 31% being added on as we go forward to capacity, but it is only to indicate the level of volatility the margin has as a direct consequence of the cost of production.
By effectively doubling the output of the facility, as we go into the early parts of next year from where we are today, we'll provide a significant, you know, a lift to our reduction of cost that is significant enough that'll make a meaningful difference to our adjusted gross margin in those future periods. But I'm not gonna provide specific guidance on it, but the lift that we've had to date is really we haven't increased capacity yet. We've just increased our planning and have done other, you know, packaging review on materials, et cetera, that have allowed us to achieve an improved margin.
We just think that by getting to this higher level of scale, that ultimately there's great opportunity for us to continue to see positive improvements to the adjusted margin that we're otherwise reporting on.
Great. Thank you. Very helpful.
Your next question comes from the line of Andrew Partheniou from Stifel GMP. Your line is open.
Good morning. Thank you for taking my question. This is Aidan Giangregorio speaking on behalf of Andrew. Just curious, diving into Quebec a little bit more, could you provide any additional color on how the sales of your products are doing specifically in the Quebec market and what's working well there?
Right. I think I would say to you that our product in Quebec is performing probably sort of flat-lining a little bit based on what we acquired, as it required a little bit of refresh. The product was in the market for a while, and the thing that we've seen over and over again is you need to have sort of new news. We have we've been working on great new innovation and upgrades that we could bring into the Quebec marketplace to make sure it continues to be a fresh offering there. Taking what is a tremendous product that was available in the Quebec market for the last year and rolling it out to some of the other markets where it's new and seeing great results as a result of that.
I think, you know, one of the things we're doing is getting the right offering into Ontario market. We've been converting from a 24-pack down to a 12-pack to make sure that the independent trade in Ontario will pick it up. Not too big a ring for them to bring it in, and we're spending a lot of time educating the budtenders on that product. We're really excited about what the Tremblant Hash could do for us. In terms of Quebec specifically, we're onto some innovation, some exciting innovation that we're you know wanna bring into the Quebec market to just keep it fresh and make sure that we maintain the momentum and some of the reasons why we bought the business.
I will say, as I mentioned earlier, that not only was the acquisition not only to get the Tremblant Laurentian brands in Quebec, but it was also to strengthen our relationship with SQDC, and we have seen a significant increase in our base organic brand business in Quebec as a result of building that relationship.
Okay. Great. Thank you for the additional color, and I'll step back in the queue.
Your next question comes from the line of Michael Freeman from Raymond James. Your line is open.
Hi, Beena. Hi, Derek. Thanks, and thanks for taking our questions, and congratulations on this booming quarter. I would like to ask some questions about the BAT PDC research alliance. Wonder if you could provide any color on focuses of this research alliance. You described sort of the R&D facilities being substantially completed now. I guess if you could describe the activity of those teams that'll be working on those innovation products, how perhaps Hyasynth cultured cannabinoid innovations might be folded into those activities. How you previously described sort of an IP-driven entry or at least approach to international and specifically U.S. markets. Wonder if you could provide some color on these things.
Certainly. First of all, with regard to the product development collaboration, as we've mentioned before, the focus is predominantly in CBD, which is the area that we're doing most of the really scientific research. The focus is looking at improving, you know, efficacy, you know, onset, you know, just the delivery mechanisms. It's a lot of fundamental research that starts with that we could then, you know, leverage as we launch new products to bring into our portfolio. The teams at the product development center and our internal R&D teams work together. As we learn more about the product, we learn how to improve the offerings that we have in our portfolio through our own R&D. That's an exciting development that's happening already.
As I mentioned, we're just completing the bio lab, and so what that means is more advanced scientific research on the plants, plant genetics is gonna happen as we move forward. That's what's happening in our PDC. In terms of Hyasynth, at this point, they're not connected, but for us, the whole focus is around innovation, and we see there's an opportunity that at some point we'll look at API that potentially is higher purity, that comes out of biosynthesis that isn't from cannabis plants that might be more appropriate for certain markets. We wanted to make sure that we have that, you know, opportunity to be connected in the biosynthesis space as well.
In terms of longer-term IP, we know that moving flower across borders is difficult, but if we develop IP, that really becomes the opportunity to take into new markets. It's something that we continue to work on together with our partners.
That's perfect. Very, very helpful. Thanks. And quickly on the 4C expansion, you mentioned that planting is gonna be happening there by the end of third quarter, harvesting in fourth quarter. Wondering how you would describe the timelines between cultivation ramp from, you know, around 50,000 kg run rate capacity sort of today to full capacity with 4C included of around 80,000 kg a year. How would you describe the timeline of that ramp?
Derek, do you want to grab that one?
Yes, I can. I would indicate that right now we're approximately at 45,000. We would leave August around 80,000 kilos a year in terms of the annualized rate. I think that the ramp is pretty heavy right now to July and August in terms of when that comes up, just as a consequence of that, you know, you have to sort of complete the construction. While we're not planting in all rooms at the same time, there is. It's going to be staggered just in terms of you know, labor management and taking into consideration the construction work. But it would be really starting to ramp up heavily into the July and August period and going from, say, 45,000 annualized kilos to the 80,000 annualized kilos.
All right. Derrick, a very quick follow-up on that. Like, I understand that escalating cultivation should improve margins based on, like, economies of scale. Might we expect a margin blip as you undergo this aggressive ramp in cultivation and planting out?
I'm not sure it would be a, you know, like a cost blip. It would be more or less there's a delay in terms of when your harvest costs that you have on it to when it hits your income statement because you almost have that 1-month delay to when the product's sold. Ultimately, in terms of all of the rooms turning, you're talking about the end of August, and that really starts to impact the cost of the inventory that's expensed during Q1 of next year.
I think there'll be, with some of the rooms coming on during, you know, some of the harvest coming on from the new rooms in June, July, that there will be some economies of scale and therefore lower costs that will benefit, you know, the Q4 margin, but that the real improvement comes after a, you know, some time has set on operating at that higher level, which again, we think we're leaving fiscal 2022 with the full capacity room harvest.
All right. Thank you very much.
So, um-
There are no further.
Thank you. I know we've run a little bit over our time, so I wanna thank everyone for joining us today. We're very excited about the momentum on our business, and we look forward to updating you on our progress. I will wish everybody a happy 4/20 for next week. With that, I'd like to end the call.
This concludes today's conference call. Thank you for your participation. You may now disconnect.